Vimarsana
Biggest News Aggregation in the World

Page 6 - History Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from History Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In History Study Today - Breaking & Trending Today

US agencies 'quietly' studying reports of post-vax neurological issues, while ghosting trial participants and sitting on data -- Health & Wellness -- Sott.net - Vimarsana News

US agencies 'quietly' studying reports of post-vax neurological issues, while ghosting trial participants and sitting on data -- Health & Wellness -- Sott.net

Two U.S. agencies have been quietly studying neurological problems that have appeared in people who have had COVID-19 vaccines, The Epoch Times has found. The Food and Drug Administration (FDA) and National Institutes of Health (NIH) have been...

Source: sott.net
US Agencies Quietly Studying Reports of Post-Vaccination Neurological Issues - Vimarsana News

US Agencies Quietly Studying Reports of Post-Vaccination Neurological Issues

Two U.S. agencies have been quietly studying neurological problems that have appeared in people who have had COVID-19 vaccines, The Epoch Times has found.

Encoded Therapeutics Presents Data Showing That Children With Dravet Syndrome Experience Early, Substantial Neurodevelopment Deficits and Seizure Burden, at the American Epilepsy Society 2021 Annual Meeting - Vimarsana News

Encoded Therapeutics Presents Data Showing That Children With Dravet Syndrome Experience Early, Substantial Neurodevelopment Deficits and Seizure Burden, at the American Epilepsy Society 2021 Annual Meeting

In addition to increased seizure frequency, the cognitive, language and motor domains are significantly affected by age two years, profoundly impacting functional abilities and an overall quality of...

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program - Vimarsana News

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced an expansion of the...

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program - Vimarsana News

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com